Tchekmedyian V, et al. - In this phase 2 trial, the outcome of multitargeted tyrosine kinase inhibitor lenvatinib was analyzed among 33 candidates with recurrent or metastatic adenoid cystic carcinoma (R/M ACC). They observed that 15.6% of patients had a confirmed partial response, 75% of patients had stable disease, 6.3% of patients discontinued treatment due to toxicity before the first scan, and 3.1% had disease progression as best response. Hypertension (28.1%) and oral pain (9.4%) were the most common grade 3 or 4 adverse events. They also noticed grade 4 adverse events like myocardial infarction, posterior reversible encephalopathy syndrome, and intracranial hemorrhage. This study showed the antitumor activity of lenvatinib in these patients, with toxicity comparable to that seen in prior studies.